Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Price Target at $34.93

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus rating of “Moderate Buy” by the eighteen brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, ten have given a buy rating and four have issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $34.9333.

DYN has been the subject of several analyst reports. Chardan Capital dropped their price objective on Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, July 29th. HC Wainwright raised their price target on Dyne Therapeutics from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Wednesday, October 8th. Evercore ISI reiterated an “outperform” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, November 14th.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN opened at $21.67 on Thursday. Dyne Therapeutics has a 12-month low of $6.36 and a 12-month high of $31.32. The company’s 50 day moving average price is $17.10 and its two-hundred day moving average price is $13.46. The firm has a market cap of $3.10 billion, a PE ratio of -5.61 and a beta of 1.16. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.05. Equities research analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $13.41, for a total transaction of $35,402.40. Following the completion of the transaction, the chief executive officer directly owned 199,539 shares in the company, valued at $2,675,817.99. The trade was a 1.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.14% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DYN. Arizona State Retirement System raised its holdings in shares of Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock worth $183,000 after buying an additional 1,481 shares in the last quarter. Y Intercept Hong Kong Ltd raised its stake in Dyne Therapeutics by 725.8% during the first quarter. Y Intercept Hong Kong Ltd now owns 80,665 shares of the company’s stock worth $844,000 after acquiring an additional 70,897 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Dyne Therapeutics by 22.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company’s stock worth $201,000 after acquiring an additional 3,496 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Dyne Therapeutics in the 1st quarter valued at approximately $1,031,000. Finally, XTX Topco Ltd acquired a new stake in shares of Dyne Therapeutics in the 1st quarter valued at approximately $330,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.